secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0000950170-25-044375
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics reports FY2024 net loss of $17.6M; $94.9M cash; raised $125M for TNX-103 Phase 3 trials
--------------------------------------------------------------------------------

- Net loss for FY2024 was $17.6M vs $7.7M in 2023; Q4 net loss $6.3M vs $3.2M.
- Cash and cash equivalents $94.9M as of Dec 31, 2024; plus $25M March 2025 private placement, funding through 2027.
- Phase 3 LEVEL study enrollment expanded to 230 patients; topline data expected mid-2026.
- Second Phase 3 study LEVEL-2 expected to initiate in 2025.
- R&D expenses $12.7M in 2024 vs $3.2M in 2023, driven by Phase 3 LEVEL study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000095017025044375/0000950170-25-044375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000095017025044375/form-8-k-ye-2024v2.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer